Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial.
The Experience Diagnosing, Understanding Care, and Treatment with Enbrel (EDUCATE) trial is a phase IV, 24-week, multicenter, open-label study of etanercept 50 mg weekly in the treatment of psoriatic arthritis (PsA) in community dermatology clinics. In this study, patients with active PsA and moderate to severe plaque psoriasis have measurable uses of healthcare resources at baseline, reflecting a burden of illness. Etanercept significantly reduced healthcare resource utilization, absenteeism, and caregiver assistance in PsA patients after 24 weeks of treatment. These results could translate into savings on both direct and indirect costs and improvements in health-related quality of life for patients with PsA.
Kimball
Alexa Boer
AB
Massachusetts General and Brigham and Women's Hospitals, Harvard Medical School, Boston, MA 02114, USA. harvardskinstudies@partners.org
Jackson
J Mark
JM
Sobell
Jeffrey M
JM
Boh
Erin E
EE
Grekin
Steven
S
Pharmd
Elaine B Yu
EB
Woolley
J Michael
JM
Xia
H Amy
HA
Chiou
Chiun-Fang
CF
Stevens
Seth R
SR
D000041:Absenteeism; D000328:Adult; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000191:economics*; D017028:Caregivers; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D003627:Data Interpretation, Statistical; D004526:Efficiency; D004651:Employment; D000068800:Etanercept; D005260:Female; D006295:Health Resources / Q000191:economics / Q000706:statistics & numerical data; D006801:Humans; D007074:Immunoglobulin G / Q000191:economics* / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000191:economics* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*
D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept